Table 2.
Comparison of baseline characteristics between the ISP and CSP groups of propensity score matching
| ISP (N = 32) |
CSP (N = 32) |
p | |
|---|---|---|---|
| Age (y.o) | 40.9 ± 12.7 | 45.7 ± 15.7 | 0.22 |
| Male gender (n [%]) | 15 (46.9) | 16 (50.0) | 0.80 |
| BMI (kg/m2) | 22.3 ± 3.9 | 22.6 ± 3.1 | 0.85 |
| HT (n [%]) | 18 (56.3) | 20 (63.0) | 0.88 |
| DM (n [%]) | 1 (3.1) | 3 (1.9) | 0.61 |
| SBP (mmHg) | 116.6 ± 14.8 | 121.5 ± 13.9 | 0.18 |
| DBP (mmHg) | 71.5 ± 11.6 | 71.8 ± 8.1 | 0.77 |
| RAS inhibitor use (n [%]) | 13 (40.6) | 19 (59.0) | 0.13 |
| Proteinuria (g/gCr) | 0.93 (0.61–1.37) | 0.91 (0.35–1.52) | 0.67 |
| Categories for proteinuria (g/gCr) | 0.17 | ||
| ≧1.0 (n [%]) | 14 (43.8) | 15 (46.9) | |
| 0.5–0.9 (n [%]) | 11 (34.4) | 5 (15.6) | |
| < 0.5 (n [%]) | 7 (21.9) | 12 (37.5) | |
| Hematuria (n [%]) | 29 (90.6) | 30 (93.8) | 0.64 |
| eGFR (mL/min/1.73 m2) | 62.5 (33.9–80.7) | 58.4 (39.2–76.6) | 0.93 |
| CKD stage | 0.22 | ||
| 1–2 (n [%]) | 18 (56.3) | 15 (46.9) | |
| 3 (n [%]) | 9 (28.1) | 15 (46.9) | |
| 4 (n [%]) | 5 (15.6) | 2 (6.2) | |
| 5 (n [%]) | 0 (0) | 0 (0) | |
| IgA (mg/dL) | 346.6 ± 147.9 | 363.6 ± 119.1 | 0.36 |
| C3 (mg/dL) | 97.4 ± 19.8 | 104.1 ± 15.5 | 0.17 |
| IgA/C3 | 3.7 ± 1.9 | 3.6 ± 1.2 | 0.73 |
| Tonsillectomy (n [%]) | 4 (12.5) | 5 (15.6) | 0.72 |
BMI body mass index, HT hypertension, DM diabetes mellitus, SBP systolic blood pressure, DBP diastolic blood pressure, RAS renin–angiotensin–aldosterone system, eGFR estimated glomerular filtration rate, CKD chronic kidney disease, IgA immunoglobulin A